- Home
- THCH vs BCAB Comparison
THCH vs BCAB Comparison
Compare THCH & BCAB Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | THCH | BCAB |
|---|---|---|
| Founded | 2018 | 2007 |
| Country | China | United States |
| Employees | N/A | N/A |
| Industry | Blank Checks | Medicinal Chemicals and Botanical Products |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 80.7M | 71.6M |
| IPO Year | N/A | 2020 |
Fundamental Metrics
Financial Performance| Metric | THCH | BCAB |
|---|---|---|
| Price | $2.27 | $0.33 |
| Analyst Decision | | Hold |
| Analyst Count | 0 | 3 |
| Target Price | N/A | ★ $1.00 |
| AVG Volume (30 Days) | 15.1K | ★ 2.4M |
| Earning Date | 12-09-2025 | 11-13-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $188,274,078.00 | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $1.95 | $0.24 |
| 52 Week High | $3.80 | $1.43 |
Technical Indicators
Market Signals| Indicator | THCH | BCAB |
|---|---|---|
| Relative Strength Index (RSI) | 47.97 | 29.87 |
| Support Level | $2.08 | $0.29 |
| Resistance Level | $2.66 | $0.41 |
| Average True Range (ATR) | 0.13 | 0.09 |
| MACD | -0.01 | -0.02 |
| Stochastic Oscillator | 41.38 | 6.38 |
Price Performance
Historical ComparisonAbout THCH TH International Limited Ordinary shares
TH International Ltd is the parent company of the franchise of Tim Hortons coffee shops and has the rights to operate Tim Hortons coffee shops in mainland China, Hong Kong, and Macau. Through the Tim Hortons brand, the firm offers freshly brewed coffee, tea, and other beverages, bakery & sides, and sandwiches. The Company operated under single reportable segment, Tim Hortons. The company's revenue is derived from its operations in the PRC.
About BCAB BioAtla Inc.
BioAtla Inc is a clinical-stage biopharmaceutical company. The company is engaged in the development of a novel class of specific and selective antibody-based therapeutics for the treatment of solid tumor cancer. Its pipeline products comprise mecbotamab vedotin (BA3011), ozuriftamab vedotin (BA3021), and evalstotug (BA3071), and its Phase 1 clinical trial of BA3182 (CAB-EpCAM x CAB-CD3) and Bispecific antibody programs.